Toronto-based BenchSci, which is using AI to accelerate drug discovery research and reduce related costs, raises $22M Series B led by F-Prime Capital
Kyle Wiggers / VentureBeat :
Context & Ripple Effects
BenchSci's $22M Series B lands mid-wave in a funding run for AI applied to biotech R&D: London's BenevolentAI had already pulled in a $115M round at a $2.1B valuation in 2018, and Benchling — the closest comparable in research-data software — closed a $34.5M Series C just months before this round. The bet here is that machine learning can cut the cost of the experiment-heavy early stages of drug discovery.
The round also fits Toronto's rise as a tech center: CBRE ranks it the third-largest North American tech hub with the fastest-growing tech workforce on the continent, and BenchSci is one of the city's marquee AI startups. The arc pays off three years later, when the company returns for a CA$95M Series D led by Generation Investment Management.
First-order effects
- F-Prime Capital's lead gives BenchSci the runway to expand its AI platform across more pharmaceutical customers, moving it from early traction toward the scale its later Series D implies.
Second-order effects
- Benchling's escalation — from its 2019 Series C to a $4B valuation in April 2021 and then a $100M Series F at $6.1B — shows what BenchSci's category rewards: once one R&D-software vendor raises big, rivals must raise comparably to keep pace on product and sales capacity.
Third-order effects
- If the pattern holds, pharma R&D tooling consolidates around a few heavily capitalized AI platforms, shifting drug-discovery budgets from internal lab spend toward licensed software — and cementing Toronto alongside Boston and San Francisco as a base for AI-biotech companies.
The trend: Venture capital is pouring progressively larger rounds into AI-native biotech R&D software, with Toronto-based BenchSci's path from Series B to Series D tracking the same curve as Benchling and BenevolentAI.